Month: October 2025

BusinessTechnology

Oracle Shares Drop Amid Questions Over AI Infrastructure Expansion Pace

Oracle Corporation experienced its steepest single-day decline in nearly nine months as investors expressed concerns about the company’s capacity to fulfill growing AI infrastructure demand. The drop came despite Oracle’s announcement of ambitious long-term revenue projections and major cloud deals with leading AI firms.

Oracle Faces Stock Decline Following AI Infrastructure Outlook

Oracle Corporation reportedly saw its shares fall as much as 8.2% on Friday, marking the company’s most significant intraday decline since January 27, according to market analysis. The drop occurred despite the technology giant announcing ambitious long-term revenue projections and securing multibillion-dollar artificial intelligence cloud contracts with major industry players.

by Carter Wells
EducationPolicy

Student Loan Forgiveness Processing Resumes Following Legal Settlement

The Department of Education has agreed to resume student loan forgiveness processing for millions of borrowers under multiple repayment plans. The settlement also provides crucial tax liability protection for those qualifying for debt discharge.

Major Breakthrough for Student Loan Borrowers

Millions of student loan borrowers have achieved a significant victory as the Department of Education has agreed to resume processing loan forgiveness that had been stalled, according to reports. The department also committed to protecting borrowers from potential tax liabilities associated with discharged debt, sources indicate.

by Carter Wells
PharmaPolicy

Trump Administration’s Pharma Deals Signal Major Policy Shift on Drug Pricing

Recent agreements between the Trump administration and major pharmaceutical companies mark a significant shift in drug pricing policy. The deals connect tariff protection to price reductions and domestic manufacturing investment, creating a new negotiation model for the industry.

New Pharmaceutical Pricing Framework Emerges

The pharmaceutical industry is facing a structural reset in how it approaches pricing and domestic investment, according to reports analyzing recent agreements between the Trump administration and major drug manufacturers. Sources indicate that deals with Pfizer and AstraZeneca establish a new framework that ties drug affordability to domestic production commitments, marking a significant departure from previous approaches to prescription drug pricing policy.

by Darren Holt